Protracted low-dose cisplatin infusion in advanced colorectal cancer.
Protracted, 24-hour, continuous-infusion cisplatin at a dose rate of 5 mg/m2/day was administered to 25 patients with advanced measurable colorectal cancer. All patients had previously received 5-FU administered on the same schedule. Sixteen patients received the infusion for greater than or equal to 14 days and were considered evaluable for response assessment. No patient achieved a response.
J
J
Lokich
T
T
Zipoli
R
R
Greene
S
S
Paul
H
H
Sonnenborn
C
C
Moore
D000553:Ambulatory Care; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D006801:Humans; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D010534:Peritoneal Neoplasms / Q000556:secondary; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology
D002945:Cisplatin